Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice | Scientific Reports
The Dose Dependent Effects of Ruxolitinib on the Invasion and Tumorigenesis in Gliomas Cells via Inhibition of Interferon Gamma-Depended JAK/STAT Signaling Pathway
The Dose Dependent Effects of Ruxolitinib on the Invasion and Tumorigenesis in Gliomas Cells via Inhibition of Interferon Gamma-Depended JAK/STAT Signaling Pathway
Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy - ScienceDirect
Survival is improved for VSV-IFNβ with the addition of ruxolitinib in a... | Download Scientific Diagram
Ruxolitinib Phosphate Datasheet
Targeting the JAK/STAT pathway in solid tumors
Inhibition of the Invasion of Human Glioblastoma U87 Cell Line by Ruxolitinib: A Molecular Player of miR-17 and miR-20a Regu
Ruxolitinib Plus Radiation and Temozolomide for Newly Diagnosed Grade III Gliomas and Glioblastoma | PracticeUpdate
TROY signals through JAK1-STAT3 to promote glioblastoma cell migration and resistance - ScienceDirect
TROY signals through JAK1-STAT3 to promote glioblastoma cell migration and resistance - ScienceDirect
Cancers | Free Full-Text | Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors—A Strategy for Hematological Malignancies? | HTML
Repurposing anticancer drugs for the management of COVID-19 - European Journal of Cancer
JCI - Immunostimulatory bacterial antigen–armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy
A STAT3-based gene signature stratifies glioma patients for targeted therapy | Nature Communications
Ruxolitinib (INCB018424) is an Orally Active JAK1 and JAK2 Inhibitor - Network of Cancer Research
Can immunotherapy tackle glioblastoma?
The Dose Dependent Effects of Ruxolitinib on the Invasion and Tumorigenesis in Gliomas Cells via Inhibition of Interferon Gamma-Depended JAK/STAT Signaling Pathway
Inhibition of tumor growth and angiogenesis of tamoxifen‑resistant breast cancer cells by ruxolitinib, a selective JAK2 inhibitor
Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy - ScienceDirect
Ruxolitinib (INCB018424) Datasheet
Significant inhibitory effect of ruxolitinib in vivo. (A) Flow chart of... | Download Scientific Diagram
Spatiotemporal activation of PDGFRα in the CNS produces proneural GBM... | Download Scientific Diagram
Perspective of mesenchymal transformation in glioblastoma | Acta Neuropathologica Communications | Full Text
Combination of VSV-GP and ruxolitinib enhances virus replication in the... | Download High-Quality Scientific Diagram
Taking on Glioblastoma Through Translational Research: 4 Promising Bench-to-Bedside Initiatives – Consult QD
